Characteristics and clinical outcomes of metastatic testicular cancer in a distinct demographic.

• DOI: 10.1200/jco.2025.43.5_suppl.620
• Publication Date: 2025-02-18T14:30:51Z
• Authors: Ayobami Gbenga Ol...; Olanipekun Lanny ...; Inimfon Nsikak Ja...; Youjin Oh; Oboseh John Ogedegbe; Hafeez Shaka

620 Background: Testicular cancer is the most common malignancy among adolescent and young adult (AYA) males (15 – 40 years). While median age at diagnosis 33 years, testicular also occurs in older aged (>40 Though it less frequent this population, important because outcomes of metastatic population are unknown. We examined inpatient characteristics for patients with a cancer. Methods: In retrospective cohort analysis using NIS database from 2008 to 2021, admitted were identified ICD codes. Descriptive analyses conducted compare sociodemographic, hospital-level clinical between AYA. Multivariate logistic linear regression models used examine association groups mortality, length stay (LOS), total hospital charges (THC). Results: There 57,366hospitalizations malignancy. Of these, 14,733 (25.7%) male cohort. The mean was 51 years group 27.3 AYA (P < 0.001). higher proportion non-Hispanic White compared (73% vs 53%, P 0.001) but lower distribution Hispanic (11% 31%, Most both cohorts had private insurance (54% 47%, P<0.001). Both admissions teaching (75.7% 84%, 0.001), urban (95.2 97.2%, P<0.001), andlarge-sized hospitals (65.5 70%, P=0.001). HIV comorbidity (0.5% 0.2%, = 0.02). mortality rate (6.2% 2.8%, over two-fold odds relative younger (aOR: 2.25, 95% confidence interval [CI]: 1.84-2.75, On subgroup analysis, black 70% 1.7, CI 1.15-2.5, p=0.008). longer LOS (β coefficient: 0.49, CI: 0.15-0.84, 0.005). THC similar two (β-Coefficient: 1,238, -4,080–6,555, 0.65). likely have retroperitoneal lymph node dissection 0.57, 0.48-0.67, Conclusions: This largest epidemiological study date on hospitalizations adults. Older patients. Racial disparities evident, Black having mortality. Our findings underscore unique that could guide patient selection future trials enhance development novel therapies population.